Jane McLelland Off Label Drugs for Cancer
Jane McLelland – How to starve cancer
Jane McLelland was first diagnosed with cervical cancer and then developed leukemia after chemotherapy treatment and was deemed Stage 4, Grade 4 in 1999. She beat her cancer by using a mixture of diet, exercise, supplements, herbs and off-label drugs to block the metabolic pathways that fuelled her cancer. Many others are now following her example. The protocols she used can be found in her book How to Starve Cancer.
Following are four of the main targets of Jane McLelland’s approach to starving cancer. Find out possible interactions between drugs and supplements here and an online drugs checker like this one.
NOTE: Some of the drugs and supplements in these protocols can interact resulting in serious side effects. They should only be taken under the supervision of your doctor.
What are metabolic pathways?
Metabolic pathways are the fuel lines cancer cell uses to grow and spread!
|Metabolic Pathways (Fuel lines)||Treatment|
|LOW GLYCAEMIC DIET|
VITAMIN C IV 2-DEOXYGLUCOSE (2DG)
DICHLOROACETATE (DCA) BROMOPYRUVATE (3BP)
|F.A.S.||METFORMIN + ASPIRIN|
Abnormal Cell Signalling
|Abnormal Cell Signalling||Treatment|
Common in MOST cancers
Common in viral induced cancers
Common in gastric, head & neck, cervical squamous, breast, colon, leukaemia, glioma and medulloblastoma cancers
Common in head & neck, gastric, colorectal, liver, pancreatic, skin, breast, ovarian and cervical cancers
Low Dose Naltrexone (LDN)
Linked to oncogenic viruses
Common in breast, ovarian, endometrial. Other cancers maybe oestrogen positive such as gastric, NSCLC, colon and liver but this is less common and you would need to test to be sure
|Indole-3-carbinol (I3C or DIM)|
Common in many cancers.
|Interleukin 1 and 6||NSAIDS like Aspirin, Flarin, etodolac|
NOTE: many NSAIDS come with the risk of gastric bleeds.
but improving gut flora is best strategy with probiotics, Omega 3, Vit A, D and Omega 7
Abnormal Growth Factors
|Abnormal Growth Factors||Treatment|
Fast Cell Division
|Fast Cell Division||Comment|
|Mebendazole||Low toxicity drug works same way as chemo. Add piperine to aid absorbtion|
|Intravenous Vitamin C||Acts like chemo drug. Lethal to stem cells. Add Doxycycline for greater effects.|
|Non- aspirin NSAIDs||Use short term. Concurrent use of a statin and Dipyridamole mitigates cardio effects and enhances efficacy.|
|Chemotherapy||Low dose is better than maximum tolerated dose which can kill you.|
|Metronomic low dose chemotherapy||Shown to boost anti-tumor T-cell immunity|
Cancer metabolism at a glance
Source: Journal of Cell Science
Cancer cells typically proliferate from one aberrant cell to more than 109 cells (the average number of cells in a tumor of ∼1 cm in diameter). To achieve and sustain that proliferative capacity, cancer cells must activate or enhance metabolic pathways (Lunt and Vander Heiden, 2011). These pathways use available nutrients to…to satisfy the energy demand for cell maintenance…
Metabolic Phenotype Tests
Metabolic Phenotype tests can provide valuable information about what is fuelling your cancer.
These fuel lines or metabolic pathways can then be targeted with therapies to limit or cut off the supply of crucial nutrients to the cancer cells in order to induce cell death.
For example, this study says breast cancer cells rely on the specific metabolic pathways in order to sustain their growth. Triple negative breast cancer (TNBC), an aggressive breast cancer subtype relies mainly on glycolysis (using glucose for cellular fuel), while estrogen receptor positive (ER+) breast cancer cells possess higher levels of OXPHOS which produces cellular energy in the form of ATP.
This study says the recent surge of interest in understanding cancer metabolism has identified several alternative fuels that tumor cells can utilize to support their metabolic needs. The dependence of tumors on these fuels reveals their unexpected metabolic flexibility to utilize a wide variety of alternative fuels.
However, this study cautions that the drawbacks of using metabolic-based therapies (e.g inhibiting glycolysis) is that they often cause non-specific toxicity to normal healthy tissues and cells. These anticancer therapies may target cells of the immune system which will reduce the immune response towards the tumor. Toxicity is also exhibited in neuronal [nerve] cells as reducing glucose levels can cause neuropathies as neurons are very energy intensive, requiring large amounts of glucose.
This Scientific Review says: We now know that cancers harbor significant genetic heterogeneity, even within a single patient. Based on this heterogeneity, cancers routinely evolve resistance to treatment through switching from one growth pathway to another… Some effort is now being made in combining targeted agents so that more than one pathway can be affected, but lack of therapeutic success, significant toxicity and costs make this a challenge.
Care Oncology Clinic (UK)
See also: Care Oncology Clinic (USA)